SCHEMBL19633355

SCHEMBL19633355

COc1cc(OC)c(Cl)c(N(C(=O)OC(C)(C)C)C(=O)N(C)c2cc(N(C(=O)OC(C)(C)C)c3ccc(N4CCC(N(C)C)CC4)cc3[N+](=O)[O-])ncn2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 10/20 0.42
▸ FGFR3 P22607 7/20 0.42
▸ FGFR4 P22455 6/20 0.42
▸ FGFR2 P21802 5/20 0.42
▸ PLK1 P53350 4/20 0.40
▸ ALK Q9UM73 4/20 0.34
▸ EGFR P00533 3/20 0.34
▸ JAK2 O60674 2/20 0.34
▸ ABL1 P00519 2/20 0.34
▸ INSR P06213 2/20 0.34
▸ LCK P06239 2/20 0.34
▸ FYN P06241 2/20 0.34
▸ YES1 P07947 2/20 0.34
▸ LYN P07948 2/20 0.34
▸ RET P07949 2/20 0.34
▸ MET P08581 2/20 0.34
▸ ROS1 P08922 2/20 0.34
▸ KIT P10721 2/20 0.34
▸ SRC P12931 2/20 0.34
▸ BRAF P15056 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19633409 0.96 FGFR1 (0.42) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL19633296 0.92 FGFR1 (0.43) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL28611756 0.90 FGFR1 (0.37) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL19633353 0.89 FGFR1 (0.44) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL20836828 0.88 FGFR1 (0.42) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL19633357 0.87 FGFR1 (0.55) FGFR1FGFR3FGFR4FGFR2PLK1
SCHEMBL20836818 0.87 FGFR1 (0.33) FGFR1FGFR3FGFR4FGFR2
SCHEMBL30745796 0.87 FGFR1 (0.33) FGFR1FGFR3FGFR4FGFR2
SCHEMBL26802384 0.85 FGFR3 (0.37) FGFR1FGFR3FGFR4FGFR2ALK
SCHEMBL17736232 0.85 KDM4E (0.32) FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018130-A1 Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2024-01-18 — — US disclosed
US-11827625-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. 2023-11-28 — — US disclosed
WO-2017198221-A1 PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE 浙江海正药业股份有限公司 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827625-B2 Pyrimidine derivative, method for preparing same and use thereof in medicine FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885
US-20240018130-A1 Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine FGFR4, FGFR1, FGFR2 FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback